Resveratrol ameliorates myocardial fibrosis by inhibiting ROS/ERK/TGF-β/periostin pathway in STZ-induced diabetic mice by unknown
RESEARCH ARTICLE Open Access
Resveratrol ameliorates myocardial fibrosis
by inhibiting ROS/ERK/TGF-β/periostin
pathway in STZ-induced diabetic mice
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Abstract
Background: Myocardial fibrosis is an essential hallmark of diabetic cardiomyopathy (DCM) contributing to cardiac
dysfunctions. Resveratrol, an antioxidant, exerts its anti-fibrotic effect via inhibition of oxidative stress, while the
underlying molecular mechanism remains largely elusive. Periostin, a fibrogenesis matricellular protein, has been shown
to be associated with oxidative stress. In the present study, we investigated the role of periostin in anti-fibrotic effect of
resveratrol in streptozocin (STZ)-induced diabetic heart and the underlying mechanisms.
Methods: Diabetic mice were induced by STZ injection. After treatment with resveratrol (5 or 25 mg/kg/day i.g)
or Saline containing 0.5 % carboxymethyl cellulose (CMC) for 2 months, the hearts were detected for oxidative stress
and cardiac fibrosis using western blot, Masson’s trichrome staining and Dihydroethidium (DHE) staining. In in vitro
experiments, proliferation and differentiation of fibroblasts under different conditions were investigated through
western blot, 3-(4,5)-dimethylthiahiazo (−z-y1)-3,5-di-phenytetrazoliumromide (MTT) assay and immunofluorescence
staining.
Results: Administration of resveratrol significantly mitigated oxidative level, interstitial fibrosis and expressions of
related proteins in STZ-induced diabetic hearts. In in vitro experiments, resveratrol exhibited anti-proliferative effect
on primary mouse cardiac fibroblasts via inhibiting reactive oxygen species (ROS)/extracellular regulated kinase
(ERK) pathway and ameliorated myofibroblast differentiation via suppressing ROS/ERK/ transforming growth factor
β (TGF-β)/periostin pathway.
Conclusion: Increased ROS production, activation of ERK/TGF-β/periostin pathway and myocardial fibrosis are
important events in DCM. Alleviated ROS genesis by resveratrol prevents myocardial fibrosis by regulating periostin
related signaling pathway. Thus, inhibition of ROS/periostin may represent a novel approach for resveratrol to
reverse fibrosis in DCM.
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Background
Diabetes mellitus (DM) is a common metabolic disease,
and cardiovascular diseases have become the principal
culprits leading to mortality in diabetic patients. An ac-
cumulating body of evidence suggests that DCM charac-
terized by both early-onset diastolic and late-onset
systolic dysfunctions independent of hypertension and
coronary artery disease is one of the major causes
leading to heart failure in diabetic patients. Despite ex-
tensive studies, a thorough understanding of the patho-
genesis has remained elusive and there are no effective
therapies for them.
Mechanistically, complex and highly diversified mecha-
nisms are involved in the pathogenesis of DCM, but of
particular importance is myocardial fibrosis. Interstitial fi-
brosis of myocardium is characterized by increased matrix
proteins accumulation due to an effect of profibrotic
growth factor, especially TGF-β. Periostin, a matricellular
protein, plays a critical role in regulating fibrogenesis of
various diseases, such as heart failure [1, 2], myocardial
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infarction [3] and idiopathic pulmonary fibrosis [4]. Peri-
ostin can be stimulated by TGF-β and can modulate ex-
pression of multiple downstream proteins including α-
smooth muscle actin (α-SMA) and collagens, which are all
involved in fibrosis [5, 6]. Though heavily studied, the pro-
fibrotic effect of periostin in DCM is still far from being
fully elucidated.
It is generally accepted that oxidative stress is an es-
sential hallmark of diabetes, moreover, activation of
ERK/TGF-β pathway and upregulated collagen produc-
tion contributed to fibrosis [7]. Considering the relation-
ship between TGF-β and periostin, we postulate that
activation of ERK/TGF-β/periostin pathway by oxidative
stress is, in part, a key event in the development of myo-
cardial fibrosis in DCM.
Given the critical role of oxidative stress in diabetes,
there are a few studies looking specially at the effect of an-
tioxidants on DCM [8]. Resveratrol, a polyphenol present
in grapes and red wine, has antioxidative effects on cardio-
vascular diseases [9]. Fragmentary data on animal experi-
ments has indicated that resveratrol could prevent fibrosis
in DCM via inhibition of oxidative stress [10], yet, the pre-
cise regulatory mechanisms are currently unknown.
Thus, this study was designed to test whether activation
of TGF-β/periostin pathway is associated with myocardial
fibrosis of DCM in STZ-induced diabetic mice and to
evaluate whether resveratrol ameliorates fibrogenesis by




The experimental and feeding protocols were in accordance
with National Health guidelines and were approved by the
Animal Care and Use Committee of the Affiliated Drum
Tower Hospital of Nanjing University Medical School.
C57BL/6 mice (male) were purchased from Model Animal
Research Center of Nanjing University. Mice were ran-
domly assigned into four groups containing eight mice
each. Diabetes mellitus was induced by consecutive intra-
peritoneal administration of STZ (40 mg/kg/day, Sigma)
dissolved in 0.1 M sodium citrate buffer, PH 4.5, for 5 days
as described [11]. Mice with a blood glucose level above
13.9 mM at 3 days after the last STZ injection were consid-
ered as diabetic animals. One month after induction of dia-
betes, mice were treated with resveratrol (5 or 25 mg/kg/
day i.g, Sigma) for another 2 months. Saline containing
0.5 % CMC (vehicle) was given as a control. Changes in
body weight and blood glucose were recorded every 2 weeks
until the animals were sacrificed.
Masson’s trichrome staining
After fixation with 4 % paraformaldehyde in phosphate-
buffered saline for 24 h, the cardiac tissues were subjected
to alcoholic dehydration and embedded in paraffin. 4 μm
serial sections were sliced and subjected to Masson’s
trichrome staining to observe the degree of myocardial fi-
brosis. Collagen volume fraction (CVF) was determined
by Image Pro Plus software, and the mean values of CVF
were obtained by one investigator blinded to the groups.
DHE staining
In this study, superoxide expression was detected by
DHE staining. The heart sections were incubated with
2 μm/ml DHE dye (Beyotime Technology) for 30 min at
37 °C protected from light. Oxidative stress was exam-
ined and captured on immunofluorescence microscope.
Red staining indicating oxidative stress was quantified
using Image Pro Plus software.
Cell culture
Primary mouse cardiac fibroblasts (mCFs) were isolated
and cultured as previously described [12]. Briefly, after
being excised from mice, the hearts were washed in cold
PBS. The ventricles were minced and digested in Dul-
becco’s modified Eagle’s medium (DMEM) containing
0.1 % collagenase type 2 (Worthington) at 37 °C with
continous shaking for 30 min. After being pre-plated for
1 h at constant incubator, the unattached cells were re-
moved and cultured in DMEM containing 10 % foetal
bovine serum (FBS).
Western blot analysis
Cells or mice heart tissues were lysed using RIPA buffer
containing a 1:100 dilution of protease inhibitor and
phosphatase inhibitor (Sigma). Protein concentrations
were determined by a BCA protein assay (Pierce), and
equal protein samples were separated by SDS-PAGE.
Proteins were transferred electrophoretically to polyviny-
lidene difluoride membranes (Millipore), and then incu-
bated in Tris-buffered saline containing 0.1 % Tween 20
(TBST) with 5 % milk for 1 h at room temperature.
Membranes were then incubated with primary anti-
bodies as follows: anti-p66shc (1:1000, Santa Cruz), anti-
p47phox (1:1000, Santa Cruz), anti-gp91phox (1:1000,
Santa Cruz), anti-α-SMA (1:1000, Abcam), anti-ERK
(1:1000, Santa Cruz), anti-pERK (1:1000, Santa Cruz),
anti-collagen I (1:500, Bioworld), anti-periostin (1:500,
Santa Cruz) and anti-TGF-β (1:500, Santa Cruz). Anti-β-
actin antibody (1:2000, Santa Cruz) was used as the in-
ternal control. After four washes in TBST, the blots were
incubated with horseradish peroxidase-conjugated sec-
ondary antibodies. The washes were repeated, and the
membranes were then treated with Super Signal Substrate
Western Blotting Reagent (Millipore). The bands were
quantified using BioRad Quantity One imaging software.
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Immunofluorescence staining
Measurement of α-SMA using immunofluorescence
staining was performed as previously described [12].
Briefly, after being placed in 24 well plates, mCFs were
washed with PBS twice and then were blocked with 1 %
bovine serum albumin at room temperature for 30 min.
Then the cells were incubated overnight with rabbit
anti-α-SMA primary antibody (1:100, Abcam). After be-
ing washed with PBS, the cells were performed with goat
anti-rabbit secondary antibody conjugated to Alexa
Fluor 488 (1:400, Invitrogen) for 1 h under dark condi-
tion. Finally, the cells were counterstained with DAPI
(Sigma) for 10 min, and were analyzed with an immuno-
fluorescence microscope.
Measurement of intracellular ROS in fibroblasts
Intracellular ROS generation was measured using fluores-
cent probe 2′,7′-dichlorofluorescin diacetate (DCFH-DA)
as previously described [12]. Briefly, mCFs were plated in
24 well plates at a density of 5 × 105 cells /well. After dif-
ferent treatments, medium was removed and the cells
were washed with PBS. A solution of 5 μM DCFH-DA
probe (Sigma) in serum free medium was then added for
30 min at 37 °C. Then intracellular ROS were detected by
immunofluorescence microscope.
MTT assay
mCFs were seeded in 96-well culture plates at 105 cells/
well. After serum starvation, the cells were treated as in-
dicated in the figure legends. The cells were washed
twice with PBS, and were resuspended in 1 ml DMEM
without FBS. After incubation with 5 mg/ml MTT
reagent (Beyotime Technology), the cells were solubilized
in DMSO to solubilize the formazan crystals. The absorp-
tion was measured by spectrophotometry at 490 nm.
Statistical analysis
Difference between two groups was analyzed by stu-
dent’s t test (normally distributed) or Mann–Whitney
(non-normally distributed). One-way analysis of vari-
ance (normally distributed) or Kruskal-Wallis test (non-
normally distributed) was used between more than two
groups. Values of p < 0.05 were considered significant.
Analyses were performed with SPSS 21.0.
Results
Changes of body weight and blood glucose with
resveratrol treatment
Four weeks after induction of diabetes, the diabetic
mice administrated with solvent or resveratrol (5 mg/
kg/day or 25 mg/kg/day) were divided into DM group,
DMR5 group and DMR25 group respectively (Fig. 1a).
The mice without injection of STZ were used as control
(N group). Changes of body weight and blood glucose
were shown in Fig. 1b, Compared with DM group, body
weight of N group increased with time passing by, while
resveratrol treatment produced a small but significant
increase in body weight in DMR25 group at the 12th
week (25.20 ± 1.57 vs 23.00 ± 1.48, p < 0.05). Blood glu-
cose was significantly higher in diabetic mice compared
with non-diabetic mice. However, resveratrol-treated
mice showed a sustained decrease in blood glucose from
8th week to the end of the study period (Fig. 1c).
Fig 1 Body weight and blood glucose levels in different groups. a Protocol for the induction of diabetes and the treatment of resveratrol. b Body
weight in non-diabetic, diabetic and resveratrol-treated diabetic mice. c Blood glucose in non-diabetic, diabetic and resveratrol-treated diabetic
mice. n = 8 in each group; *p < 0.05 vs DM group; **p < 0.01 vs DM group
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Resveratrol attenuated myocardial fibrosis and oxidative
stress in STZ-induced diabetic heart
To assess the impact of resveratrol on diabetes-induced
myocardial fibrosis, Masson’s trichrome staining was
performed. As shown in Fig. 2a, myocardial fibrosis was
significantly increased in the diabetic mice compared with
control mice (11.42 ± 1.79 vs 4.37 ± 0.99, p < 0.01). Inter-
estingly, high dose (25 mg/kg/day) resveratrol treatment
remarkably suppressed the diabetes-induced fibrosis (6.54
± 0.87 vs 11.42 ± 1.79, p < 0.05), however, low dose (5 mg/
kg/day) resveratrol showed no effect on diabetes-induced
myocardial fibrosis(9.39 ± 1.08 vs 11.42 ± 1.79, p > 0.05).
To evaluate the effects of resveratrol on oxidative stress in
diabetic hearts, superoxide expression was detected by
DHE staining. Fig 2b depicted significantly higher DHE
expression in hearts of DM group, which was significantly
inhibited in DMR25 group (159.10 ± 34.60 vs 337.00 ±
59.20, p < 0.05). Furthermore, the antioxidative effect of
resveratrol was supported by western blot assay, in which
several oxidative stress related proteins, such as p47phox,
gp91phox and p66shc were detected. Diabetic mice exhib-
ited increased expressions of these proteins compared
with control mice, while treatment with resveratrol partly
normalized their expressions in diabetic mice (Fig. 2c, d, e,
f ).
Resveratrol regulated ERK/TGF-β/periostin pathway in
diabetic hearts
To study how resveratrol modulates myocardial fibrosis
induced by diabetes, western blot was performed to ana-
lyse the protein expressions of pERK, ERK, TGF-β and
periostin, which were considered to be involved in fibro-
sis. As shown in Fig. 3, expressions of TGF-β and perios-
tin were significantly elevated in diabetic mice compared
with control mice (1.45 ± 0.13 vs 1.00 ± 0.07, p < 0.05
and 1.34 ± 0.07 vs 1.00 ± 0.11, p < 0.05 respectively), and
the upregulation of periostin was attenuated by treat-
ment of high dose resveratrol (Fig. 3b; 0.99 ± 0.09 vs
1.34 ± 0.07, p < 0.05), while TGF-β was inhibited by both
low and high dose resveratrol (Fig. 3c; 1.14 ± 0.11 vs 1.45
± 0.13, p < 0.05 and 1.08 ± 0.10 vs 1.45 ± 0.13, p < 0.05 re-
spectively). As well as periostin, activation of ERK was also
reduced in DMR25 group compared with DM group
(Fig. 3d; 0.86 ± 0.12 vs 1.43 ± 0.07, p < 0.05).
Resveratrol inhibited high glucose (HG)-induced
differentiation of mCFs via diminution of ROS production
It is widespread agreement that activity or differentiation
of fibroblasts is a critical feature of progressive fibrosis
and is associated with oxidative stress, therefore, it is ra-
tional to presume that resveratrol may suppress fibro-
blasts activity via inhibition of oxidative stress. So an in
vitro assay was performed to ascertain the effect of
resveratrol on differentiation of mCFs and to explore the
underlying mechanism.
To determine the effect of HG on differentiation of
fibroblasts in vitro, mCFs were incubated with 5.5–
45.5 mmol/l glucose for 24 h, and mannitol was used as
a control to exclude the effect of hyperosmosis. Western
blot analysis revealed an upregulation of both α-SMA
and collagen I in glucose-induced mCFs in a dose
dependent manner, and it reached a significant differ-
ence at 25.5 mmol/l (Fig. 4a, b; 2.00 ± 0.16 vs 1.00 ± 0.20,
p < 0.01 and 1.34 ± 0.15 vs 1.00 ± 0.15, p < 0.05 respect-
ively). Thus, mCFs stimulated with 25.5 mmol/l glucose
for 24 h were selected for the following studies. Then,
HG-stimulated mCFs were pretreated with resveratrol at
different concentrations (10, 20, 40 μmol/l). Resveratrol
significantly normalized the elevated expression of α-SMA
induced by HG at 20 μmol/l (Fig. 4c; 1.14 ± 0.18 vs
1.81 ± 0.21, p < 0.01), which was similar to treatment of
NAC (Fig. 4d). Therefore, immunofluorescence assay
was performed by incubation of resveratrol at 20 μmol/l
and NAC in the next study. As illustrated in Fig. 4e and f,
addition of NAC blunted ROS generation using DCFH-
DA, which was paralleled by the diminution of α-SMA
level using immunofluorescence assay, and the effects
were mimicked by the addition of resveratrol. Addition-
ally, the effects of combined incubation with resveratrol
and NAC on HG-induced mCFs were similar to that with
either agent alone.
Resveratrol inhibited HG induced mouse fibroblasts
proliferation via inhibition ofROS/ERK pathway
Proliferation of fibroblasts has been recognized as an im-
portant component in the progress of fibrosis, thus, the
effect of resveratrol on proliferation of mCF induced by
HG was investigated in this study.
The results of MTT assay showed that there was a
slight but significant increase of mCFs induced by HG
for 24 h (Fig. 5a). So we took 24 h as a proper time to
explore the effect of resveratrol on proliferation of
mCFs. As shown in Fig. 5b, the OD490 values were re-
versed to normal by the the administration of resvera-
trol, NAC, or both of them.
It is widely assumed that ERK has a positive regulatory
role in proliferation response to an array of stimuli, so
western blot was performed to study the role of ERK in
amelioration of proliferation by resveratrol. As illus-
trated in Fig. 5c, HG (25.5 mmol/l) induced significant
increase of about 50 % in phosphorylation of ERK, while
a non-significant increase was noted for equal osmolality
(glucose (Glc) 5.5 mmol/l + mannitol (Man) 20 mmol/l).
HG-induced activity of ERK was abrogated at least partly
by pretreatment of resveratrol or NAC (1.17 ± 0.17 vs
1.46 ± 0.12, p < 0.05 and 1.14 ± 0.09 vs 1.46 ± 0.12, p < 0.05),
while compounds of resveratrol and NAC did not exert a
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Fig 2 Effect of resveratrol on myofibrosis and oxidative stress in diabetic hearts. a Representative microphotographs of Masson’s trichrome
staining heart section of four groups (A1, N group; A2, DM group; A3, DMR5 group; A4, DMR25 group; A5, Quantitative analysis of CVF). b Representative
microphotographs of DHE staining in heart sections in each group (B1, N group; B2, DM group; B3, DMR5 group; B4, DMR25 group; B5, Quantitative
analysis of DHE staining). c Western blot of oxidative stress related proteins in different groups. d Quantitative analysis of p66shc. e Quantitative analysis of
gp91phox. f Quantitative analysis of p47phox. n= 8 in each group; *p< 0.05 between two groups; **p< 0.01 between two groups; bar = 50 μm
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synergistic effect on expression of pERK (Fig. 5d). In
addition, HG-induced proliferation of mCFs was sup-
pressed by pretreatment of U0126 (10 μmol/l), an in-
hibitor of ERK-activating kinases (MEK) (0.33 ± 0.02 vs
0.37 ± 0.01, p < 0.05) (Fig. 5e).
ERK/TGF-β/periostin pathway is involved in differentiation
of mCFs
To investigate the role of ERK/TGF-β pathway in ROS-
induced periostin expression in more detail, we performed
an in vitro experiment on mCFs using neutralizing anti-
body. Fig 6a showed that resveratrol and NAC had a sig-
nificant inhibitory effect on elevated expression of TGF-β
induced by HG (1.01 ± 0.10 vs 1.38 ± 0.10, p < 0.05 and
1.10 ± 0.10 vs 1.38 ± 0.10, p < 0.05 respectively). Then we
asked whether HG regulated expression of TGF-β via
ERK mediated pathway. It was observed that HG-induced
upregulation of TGF-β was suppressed by U0126, an in-
hibitor of MEK (1.05 ± 0.11 vs 1.74 ± 0.10, p < 0.05), sug-
gesting the involvement of ERK in HG-induced TGF-β
expression (Fig. 6b). As shown in Fig. 6c, d, e, after being
cultured with TGF-β, mCFs exhibited elevated α-SMA
and periostin expressions (1.10 ± 0.11 vs 1.45 ± 0.07,
p < 0.05 and 1.10 ± 0.10 vs 1.57 ± 0.13, p < 0.05 respect-
ively), which were similar to the effects of HG. Further-
more, pretreatment with TGF-β neutralizing antibody
partly corrected the dysregulations of α-SMA and perios-
tin induced by HG (Fig. 6d, e; 1.10 ± 0.11 vs 1.47 ± 0.10,
p < 0.05 and 1.10 ± 0.10 vs 1.54 ± 0.08, p < 0.05 respectively).
Discussion
Here we show that periostin is involved in myocardial fi-
brosis in STZ-induced type 1 diabetic mice. Furthermore,
resveratrol suppresses HG-induced differentiation of
mCFs via ROS/ERK/TGF-β/periostin pathway and sup-
presses HG-induced proliferation of mCFs via ROS/
ERK pathway. Our results suggest that ROS/ERK/TGF-
β/periostin pathway may contribute to myocardial fi-
brosis in DCM and resveratrol has a therapeutic po-
tential in ameliorating these processes.
Resveratrol is a naturally existing phytoalexin found
largely in grapes. It exerts potent antioxidant effects and
cardioprotective effects, including myocardial ischemia-
reperfusion injury [13], cardiomyocyte hypertrophy [10],
myocardial inflammation [14] and atherosclerosis [9].
Here, our in vitro experiments demonstrated that resver-
atrol treated group manifested less fibrosis level than no
resveratrol treated group, evidenced by a significant de-
crease in CVF using Masson’s trichrome staining. This
was accompanied by decreased oxidative stress evidenced
by downregulation of p47phox, p66shc, gp91phox and
ROS level. Supporting these statements, Qin et al. demon-
strated that reduction of oxidative stress was a potential
mechanism contributed to the beneficial effects of resvera-
trol in diet-induced metabolic heart disease in mice [10].
However, the exact mechanisms remain poorly under-
stood, which was heavily studied in this present study.
Periostin, a secreted extracellular matrix (ECM) pro-
tein, is upregulated dramatically under transverse aortic
constriction (TAC) stress [2, 15, 16], myocardial infarc-
tion [3, 17] or heart failure [1]. An accumulating body of
evidence suggests that periostin plays an important role
in fibrosis by regulating ECM molecules such as collagen
and fibronectin [18]. The importance of periostin in
fibrogenesis was also documented in studies utilizing
periostin knock-out animal, where deletion of periostin
Fig 3 Effect of resveratrol on ERK/TGF-β/periostin signaling pathway in hearts of STZ-induced diabetic mice. a Representative immunoblots of
pERK, ERK, TGF-β and periostin in the hearts of each group. b Quantitative analysis of periostin protein expression. c Quantitative analysis of
TGF-β protein expression. d Quantitative analysis of ERK activity. n = 8 in each group; *p < 0.05 between two groups; **p < 0.01 between two groups
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dramatically suppressed muscular fibrosis [19]. However,
to our knowledge, there was little information about its
profibrotic effect in DCM to date. In our diabetic mice,
periostin expression was significantly increased in
diabetic hearts compared with nondiabetic hearts. In
cultured mCFs, HG induced the protein level of perios-
tin, which was accordance to previous studies of rat car-
diac fibroblasts [20]. Interestingly, administration of
resveratrol partly blunted these changes, suggesting that
resveratrol may suppress interstitial fibrosis via inhib-
ition of periostin.
CFs, the predominant cells in ventricular, mediates
cardiac fibrosis via their proliferation and differentiation
into myofibroblasts. Proliferation and differentiation of
mCFs to myofibroblast phenotype can contribute to ex-
cessive secretion of ECM proteins and then promote
cardiac fibrosis [21]. So the precise mechanisms how
resveratrol suppresses the proliferation and differentiation
Fig 4 HG-induced differentiation of mCFs was attenuated by resveratrol and NAC. a Effect of different glucose concentrations on the expression
of α-SMA in mCFs. b Effect of different glucose concentrations on the expression of collagen I in mCFs. c Resveratrol attenuated upregulated
α-SMA expression induced by HG in a dose dependent manner. d NAC mimicked the effect of resveratrol on expression of α-SMA induced by
HG. e Immunofluorescence assay showed inhibition of ROS by resveratrol and NAC (E1, control group; E2, HG group; E3, HG + Res group;
E4, HG + NAC group; E5, HG + Res + NAC group). f Upregulated α-SMA expression induced by HG was attenuated by resveratrol and NAC using
immunofluorescence assay(F1, control group; F2, HG group; F3, HG + Res group; F4, HG + NAC group; F5, HG + Res + NAC group). * p < 0.05
between two groups; **p < 0.01 between two groups; bar = 50 μm
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of mCFs induced by HG were also investigated in this
study.
Evidence has accumulated that ERK signaling activation
was involved in fibroblast proliferation under various
stimulation [22–24]. Here, we found a significantly in-
creased proliferation and activity of ERK under high glu-
cose condition, while U0126, an inhibitor of MEK,
ameliorated mCFs proliferation induced by HG. These re-
sults suggested that HG promoted mCFs proliferation via
ERK related signaling pathway, which supported previous
observations that ERK was an important mediator in
fibroblast proliferation induced by HG, angiotensin II
(AngII), TGF-β or basic fibroblast growth factor (bFGF)
[22–24]. However, the role of ERK in the amelioration of
HG-induced mCFs proliferation by resveratrol is poorly
understood. As mentioned above, oxidative stress plays a
central role in fibrosis of DCM. Therefore, we postulated
that ROS production was an important contributing factor
for active ERK in DCM. In this investigation, we reported
that administration of resveratrol significantly decreased
ERK phosphorylation both in vitro and in vivo. Further-
more, NAC, an antioxidant, mimicked the effect of res-
veratrol. Collectively, these data demonstrated that
resveratrol mitigated HG-induced mCFs proliferation
via inhibition of ROS/ERK pathway. In favor of these re-
sults, Li et al. recently found that α-lipoic acid (ALA),
another antioxidant, favorably shifted redox homeosta-
sis and suppressed ERK activation in diabetic hearts [8].
Differentiation of myofibroblast, as evidenced by α-
SMA and collagens expression, is largely mediated by
TGF-β [21]. TGF-β has been proposed a profibrotic fac-
tor to promote the synthesis of ECM and contribute to
cardiac fibrosis [21, 25, 26]. In addition, it is generally
accepted that AngII induced increased expression of
TGF-β in CFs [27, 28], and several studies have shed
light on the effect of ERK signaling on AngII-induced
TGF-β expression [28–30]. Likewise, in this study,
addition of MEK inhibitor U0126 normalized the
Fig 5 Resveratrol retarded HG-induced proliferation of mCFs via inhibition of ROS/ERK pathway. a HG time dependently promoted proliferation
of mCFs. b Resveratrol as well as NAC inhibited proliferation of HG-induced mCFs. c HG upregulated ERK activity in a time dependent manner.
d Resveratrol and NAC suppressed the elevated ERK activity induced by HG. e HG-induced proliferation of mCFs was normalized by U0126.
*p < 0.05 between two groups; **p < 0.01 between two groups; bar = 50 μm
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elevated TGF-β induced by HG, suggesting that HG in-
creased expression of TGF-β via ERK signaling pathway.
Furthermore, in vitro and in vivo experiments demon-
strated that resveratrol treatment significant abolished
the upregulation of pERK and TGF-β in diabetic heart
or HG condition, which was in line with two novel stud-
ies showing that resveratrol inhibited high glucose-
induced TGF-β in cardiac fibroblasts [25, 26]. These re-
sults suggested that resveratrol could ameliorate TGF-β
expression via ROS/ERK pathway.
In addition to Smad2/3 activation, increasing evidence
supported the involvement of periostin in TGF-β induced
fibrosis [6, 28, 31–33]. Most studies agreed that periostin
was a downstream signal molecule of TGF-β and partici-
pated in TGF-β-induced cardiac fibrosis [5, 34]. In this
present study, anti-TGF-β antibody attenuated HG-induced
periostin expression, which showed the involvement of
TGF-β in upregulated periostin expression induced by HG.
To our knowledge, this study is the first attempt to block
the upregulated expression of periostin as well as myocar-
dial fibrosis in vivo by daily treatment with resveratrol.
Thus it provides a novel mechanism by which resveratrol
inhibited diabetes-induced fibrosis in myocardium.
Conclusions
Taken all the results above together, our investigation
demonstrates that periostin is a central element in dia-
betes related myocardium fibrosis, which is prevented by
resveratrol via inhibition of ROS/ERK/TGF-β pathway.
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Fig 6 HG increased expression of periostin via ROS/ERK/TGF-β pathway. a Resveratrol inhibited expression of TGF-β in HG-treated myofibroblasts
as well as NAC. b Treatment with U0126 suppressed the elevated TGF-β induced by HG in myofibroblasts. c HG-induced increased expressions of
periostin and α-SMA were suppressed by pretreatment with TGF-β neutralizing antibody. d Quantitative analysis of periostin. e Quantitative analysis of
α-SMA. *p < 0.05 between two groups; **p < 0.01 between two groups
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